Clinical trialPhase 3Completed
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas
- Outcome
- Outcome unknown
- Phase
- Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- 1 March 2009
- Expected end
- 9 April 2013
- Enrollment
- 861 participants
- Sites
- 193
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Industry
- Results posted
- 2013-12-11
- Last update
- 25 November 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 16
- Registry-listed results paperCA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-pac… DOI 10.1093/annonc/mdw006↗
- Registry-listed results paperPositron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcit… DOI 10.1093/annonc/mdw020↗
- Registry-listed results paperDevelopment of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcit… DOI 10.1016/j.ejca.2015.10.017↗
- Registry-listed results paperNab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- Registry-listed results papernab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. DOI 10.1093/jnci/dju413↗
- Registry-listed results paperFirst-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. PMID 25398812↗
- Registry-listed results paperIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗
- Builds on itAnalysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Tri… DOI 10.1002/onco.13645↗
- Builds on itAberrant signaling pathways in pancreatic cancer: a two compartment view. DOI 10.1002/mc.20827↗
- Backgroundnab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of… DOI 10.2147/ott.s124097↗
- BackgroundTumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory… DOI 10.1097/mpa.0000000000000742↗
- BackgroundEfficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to… DOI 10.1186/s12885-016-2798-8↗
- BackgroundSecond-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic … DOI 10.1038/bjc.2016.185↗
- BackgroundDose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreat… DOI 10.21037/jgo.2016.01.03↗
- Backgroundnab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subg… DOI 10.1007/s12325-016-0327-4↗
- BackgroundPrognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus… DOI 10.1634/theoncologist.2014-0394↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.